An economic model comparing linezolid and vancomycin for treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

被引：0
|
作者：
Patel, Dipen A. [1 ]
Shorr, Andrew F. [2 ]
Chastre, Jean [3 ]
Niederman, Michael [4 ]
Simor, Andrew [5 ]
Stephens, Jennifer M. [1 ]
Bhatt, Gaurang [6 ]
Charbonneau, Claudie [7 ]
Gao, Xin [1 ]
Nathwani, Dilip [8 ]
机构：
[1] Pharmerit Int, Bethesda, MD USA
[2] Washington Hosp Ctr, Washington, DC 20010 USA
[3] Hop La Pitie Salpetriere, Paris, France
[4] Winthrop Univ Hosp, Mineola, NY 11501 USA
[5] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[6] Pfizer Inc, Collegeville, PA USA
[7] Pfizer PIO, Paris, France
[8] Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland
来源：
PHARMACOTHERAPY | 2013年 / 33卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
107
引用
收藏
页码：E214 / E214
页数：1
相关论文
共 50 条
  • [1] An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany
    Patel, Dipen A.
    Michel, Andre
    Stephens, Jennifer
    Weber, Bertram
    Petrik, Christian
    Charbonneau, Claudie
    INFECTION AND DRUG RESISTANCE, 2014, 7 : 273 - 280
  • [2] AN ECONOMIC MODEL TO COMPARE LINEZOLID AND VANCOMYCIN FOR THE TREATMENT OF CONFIRMED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS NOSOCOMIAL PNEUMONIA IN GERMANY
    Patel, D. A.
    Michel, A.
    Stephens, J. M.
    Weber, B.
    Gao, X.
    Charbonneau, C.
    VALUE IN HEALTH, 2013, 16 (07) : A354 - A354
  • [3] AN ECONOMIC MODEL TO COMPARE LINEZOLID, VANCOMYCIN, AND TEICOPLANIN FOR THE TREATMENT OF CONFIRMED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS NOSOCOMIAL PNEUMONIA IN BRAZIL
    Niederman, M. S.
    Patel, D.
    Li, J. Z.
    Charbonneau, C.
    Ferreira, C. N.
    Figueiredo, L.
    Stephens, J. M.
    Haider, S.
    VALUE IN HEALTH, 2015, 18 (03) : A236 - A236
  • [4] Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
    Dipen A Patel
    Andrew F Shorr
    Jean Chastre
    Michael Niederman
    Andrew Simor
    Jennifer M Stephens
    Claudie Charbonneau
    Xin Gao
    Dilip Nathwani
    Critical Care, 18
  • [5] Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
    Patel, Dipen A.
    Shorr, Andrew F.
    Chastre, Jean
    Niederman, Michael
    Simor, Andrew
    Stephens, Jennifer M.
    Charbonneau, Claudie
    Gao, Xin
    Nathwani, Dilip
    CRITICAL CARE, 2014, 18 (04)
  • [6] Linezolid for the Treatment of Nosocomial Pneumonia Due to Methicillin-Resistant Staphylococcus aureus
    Wolff, Michel
    Mourvillier, Bruno
    CLINICAL INFECTIOUS DISEASES, 2012, 55 (01) : 160 - 161
  • [7] Linezolid Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: Controversy Continues
    Masuta, Kana
    Oba, Yuichiro
    Iwata, Kentaro
    CLINICAL INFECTIOUS DISEASES, 2012, 55 (01) : 161 - 161
  • [8] Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia -: The subtleties of subgroup analyses
    Powers, JH
    Ross, DB
    Lin, D
    Soreth, J
    CHEST, 2004, 126 (01) : 314 - 315
  • [9] Vancomycin Versus Linezolid in the Treatment of Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: Implications of the ZEPHyR Trial
    Alaniz, Cesar
    Pogue, Jason M.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (10) : 1432 - 1435
  • [10] Vancomycin dosing for methicillin-resistant staphylococcus aureus nosocomial pneumonia
    Hall, Ronald G., II
    CHEST, 2007, 132 (03) : 1100 - 1101
12345